AAI and Emisphere agree synergistic drug delivery alliance

US-based biopharmaceutical company, Emisphere Technologies and AAIPharma Inc have entered into an alliance that will expand the application of Emisphere's drug delivery technology Eligen and AAIPharma's drug development services.

AAIPharma works with pharmaceutical and biotech companies on product development services and currently provides drug product formulation development services to Emisphere.

Emisphere focuses on improved delivery of therapeutic molecules and nutritional supplements using its Eligen technology. The key benefit of the technology is that it improves the ability of the body to absorb small and large molecules. These molecules with poor bioavailability may be currently delivered by injection. The Eligen technology can mean the development of other routes of administration such as oral, buccal, rectal, inhalational, intra-vaginal or transdermal.

"This relationship expands Emisphere's access to new therapeutic candidates for its Eligen Technology, which potentially could lead to new products for Emisphere's pipeline and to new alliance agreements as well," said Michael Novinski, president and ceo of Emisphere. "We are also pleased that a global provider of pharmaceutical product development services with the stature of AAI has chosen to combine with Emisphere in a synergistic alliance that will benefit both organizations," Novinski added.